2 Overlooked Oil Stocks to Buy Now Before They Soar
Occidental Petroleum and Ardmore Shipping are both benefiting from higher oil prices.
ASC - Ardmore Shipping Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$19.00
LOW:
$19.00
MEDIAN:
$19.00
CONSENSUS:
$19.00
UPSIDE:
0.90%
Stock News
M&S buys mothballed fulfilment centre from Asos for £67m
ASOS PLC (LSE:ASC) has agreed to sell its Lichfield fulfilment centre to Marks and Spencer Group PLC (LSE:MKS) as the online fashion retailer continues efforts to strengthen its balance sheet and cut costs. The group said the £67.5 million disposal will generate net proceeds of at least £66 million and annual cash savings of about £6 million from lower rent and occupancy costs.
3 Small-Cap Stocks to Buy Before May 15
Tom Yeung here with your Sunday Digest.
Ardmore Shipping Q1 Earnings Call Highlights
Ardmore Shipping NYSE: ASC reported higher first-quarter adjusted earnings and raised its dividend payout ratio, while management said disruption in the Middle East is tightening an already firm product tanker market and accelerating momentum into the second quarter.
Ardmore Shipping: Doubling The Payout Turns It Into A Buy (Ratings Upgrade)
Ardmore Shipping is upgraded to buy following a surprise doubling of its dividend payout ratio to 66% of earnings. ASC's robust financial position, low leverage, and asset sales at record valuations support capital returns and future fleet growth. Q2 MR tanker rates near $50,000/day drive expected annualized dividend yields close to 20% and EPS around $1.25.
Ardmore Shipping Corporation (ASC) Q1 2026 Earnings Call Transcript
Ardmore Shipping Corporation (ASC) Q1 2026 Earnings Call Transcript
Ardmore Shipping Corporation Announces Financial Results For The Three Months Ended March 31, 2026
HAMILTON, Bermuda, May 7, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three months ended March 31, 2026. Highlights and Recent Activity Reported Adjusted earnings and net income attributable to common stockholders of $23.6 million for the three months ended March 31, 2026, or $0.58 Adjusted earnings per basic and diluted share, compared to Adjusted earnings and net income attributable to common stockholders of $5.6 million, or $0.14 Adjusted earnings per basic and diluted share for the three months ended March 31, 2025.
Ardmore Shipping Announces First Quarter 2026 Conference Call and Webcast
HAMILTON, Bermuda, April 29, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that the Company plans to announce its first quarter earnings before the market opens on Thursday, May 7, 2026 and will host a conference call later in the day at 10:00 a.m. Eastern Time.
Ardmore Shipping Provides Update on Fleet Investment, Dividend Policy, and Vessel Sale
Signed contracts for the construction of two option two 40,500 dwt IMO2 product/chemical tankers Doubling dividend payout ratio to two-thirds of adjusted earnings, effective 1Q 2026 Agreed sale of one 2014-built MR tanker for $35.5 million with June delivery MR Spot TCEs of $33,700 per day for 1Q 2026 and fixed $50,000 per day in 2Q 2026 to-date HAMILTON, Bermuda, April 29, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today provided the following update on capital allocation, vessel sale, and latest TCE guidance. Fleet Investment The Company signed contracts for the construction of two highly-efficient and versatile 40,500 dwt Handysize product/chemical tankers at Wuhu Shipyard, at a price of $44.9 million per vessel, inclusive of approximately $3 million for full IMO2 specification and MarineLine tank coatings.
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026.
Asos climbs as profit margins show improvement, with analysts wanting more stability
Shares in ASOS PLC (LSE:ASC) climbed over 9% to 245.88p, a six-week high, as the online clothing retailer reported improving profitability in the first half. Gross margins expanded more than three percentage points to around 48.5%, enabling adjusted EBITDA to increase 51% to £64 million.
A Look at Ardmore Shipping Corp (ASC) After 4.8% Gain -- GF Value $9.16 vs Price $16.24
On April 22, 2026, Ardmore Shipping Corp (ASC) shares rose 4.8% to close at $16.24. This price is within a 52-week range of $8.89 to $16.91, reflecting a strong
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study . The fixed dose combination had excellent oral bioavailability, drug exposure and a half -life of up to 12 hours.
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks.
Ardmore Shipping Files 2025 Annual Report on Form 20-F
HAMILTON, Bermuda, March 6, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F") with the U.S. Securities and Exchange Commission (the "SEC"). In compliance with the New York Stock Exchange rules, a copy of the Form 20-F can be found in the Investor Relations section of the Company's website, www.ardmoreshipping.com, under SEC Filings.
Brokerages Set Ardmore Shipping Corporation (NYSE:ASC) Target Price at $13.67
Ardmore Shipping Corporation (NYSE: ASC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to
Ardmore Shipping Corporation (ASC) Analyst/Investor Day Transcript
Ardmore Shipping Corporation (ASC) Analyst/Investor Day Transcript
Ardmore Shipping Corporation Announces Financial Results For The Three and Twelve Months Ended December 31, 2025
HAMILTON, Bermuda, Feb. 12, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and twelve months ended December 31, 2025. Highlights and Recent Activity Reported Adjusted earnings of $11.6 million and net income attributable to common stockholders of $9.3 million for the three months ended December 31, 2025, or $0.28 Adjusted earnings per basic and diluted share, compared to Adjusted earnings of $10.3 million and net income attributable to common stockholders of $5.1 million, or $0.25 Adjusted earnings per basic and diluted share for the three months ended December 31, 2024.
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. - I n NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once - daily dosing for 7 days.
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne.
Price Targets
Ardmore Shipping price target lowered to $19 from $21 at Evercore ISI
$19.00
(was $15.49)
Evercore ISI
Ardmore Shipping price target raised to $15 from $13 at Evercore ISI
$15.00
(was $12.44)
Jonathan Chappell
·
Evercore ISI
Ardmore Shipping Corporation (ASC) PT Raised to $13 at Evercore ISIMember Login
$13.00
(was $10.72)
Evercore ISI
Ardmore Shipping downgraded to Hold from Buy at Stifel
$17.00
(was $16.22)
longer ton-miles
·
Stifel Nicolaus
Ardmore Shipping price target raised to $24 from $22 at Stifel
$24.00
(was $21.30)
Benjamin Nolan
·
Stifel Nicolaus
Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields
$20.00
(was $16.35)
Omar Nokta
·
Jefferies
Jefferies Maintains Buy on Ardmore Shipping, Raises Price Target to $17
$17.00
(was $15.20)
Jefferies
HC Wainwright & Co. Maintains Buy on Ardmore Shipping, Raises Price Target to $8.5
$8.50
(was $5.51)
H.C. Wainwright